Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study - 16/05/24
, Yong Joon Kim c, #, ⁎
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | People with uveitis history are more likely to experience another uveitis event than those without it. |
• | Uveitis after COVID-19 vaccination is mostly attributed to patient's characteristics. |
• | Regardless of previous uveitis history, COVID-19 vaccine does not increase uveitis risk. |
Résumé |
Purpose |
To investigate the risk of noninfectious uveitis following the first dose of coronavirus disease 2019 (COVID-19) vaccination based on the uveitis history.
Design |
Retrospective matched cohort and crossover case series study.
Methods |
A random sample of 7 917 457 individuals who received COVID-19 vaccine between January 2021 and March 2022 in Korea, and had no recorded history of COVID-19 were categorized into the control and uveitis groups based on their uveitis history. After performing 3:1 propensity score matching, we assessed the cumulative incidence and risk of noninfectious uveitis in the 180 days after COVID-19 vaccination. Additionally, we performed a crossover case series analysis to compare the pre- and postvaccination incidence rate ratios (IRRs) of uveitis in individuals with and without a history of uveitis.
Results |
In the matched cohort analysis, uveitis group had a significantly higher cumulative incidence of uveitis (15.4%) than control group (0.10%). The uveitis group exhibited increased risks of all uveitis types, anterior, and nonanterior uveitis in the first 60 days (hazard ratio [HR]: 169, 158, and 253, respectively) and in days 61 to 180 (HR: 166, 164, and 143, respectively) after vaccination. In the crossover case series analysis, uveitis occurred with relatively equal frequency in 20-day intervals during the 180 days before and after vaccination, regardless of uveitis history. For uveitis group, the adjusted IRRs for early and late postvaccination events were 0.92 (95% CI, 0.88-0.96) and 0.83 (95% CI, 0.80-0.85), respectively.
Conclusions |
COVID-19 vaccination did not increase the risk of uveitis, regardless of uveitis history.
Le texte complet de cet article est disponible en PDF.Plan
| Supplemental Material available at AJO.com. |
|
| Meeting Presentation: This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. |
Vol 262
P. 125-133 - juin 2024 Retour au numéro
Article précédent
- AFG3L2 and ACO2-Linked Dominant Optic Atrophy: Genotype–Phenotype Characterization Compared to OPA1 Patients
- Giulia Amore, Martina Romagnoli, Michele Carbonelli, Maria Lucia Cascavilla, Anna Maria De Negri, Arturo Carta, Vincenzo Parisi, Antonio Di Renzo, Costantino Schiavi, Chiara Lenzetti, Corrado Zenesini, Danara Ormanbekova, Flavia Palombo, Claudio Fiorini, Leonardo Caporali, Valerio Carelli, Piero Barboni, Chiara La Morgia
- Clinical, Diagnostic, and Treatment Characteristics of Orbital Liposarcoma
- Wei Wu, Xin Kang, Wei Fang, Yueyue Li, Rui Ma, Mingshen Ma, Yan Hei, Qi Wang, Xiaoyi Wang, Xuetao Mu, Shuixi Zhao, Xinji Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.